Also, studies with RA patients who do not have diabetes could show whether IL-1 inhibitor therapy can prevent prediabetes and T2DM in specific patient risk groups, such as those who have RA and obesity or metabolic syndrome [100]. This evidence concerns the gene IL1A and obesity due to melanocortin 4 receptor deficiency.